Approaches to psychopharmacology

The Neurobiology of Autism

Volumn , Issue , 2005, Pages 79-102

  Steingard, Ronald J ^a   Connor, Daniel F ^a   Au, Trang ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548112347     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (66)

1. Alcami Pertejo M, Peral Guerra M, Gilaberte I. 2000. [Open study of fluoxetine in children with autism]. Actas Espanolas Psiquiatria 28:353-56. (In Spanish.)
2. Aman MG, Langworthy KS. 2000. Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord 30:451-59.
3. Aman MG, Marks RE, Turbott SH, et al. 1991a. Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry 30:246-56.
4. Aman MG, Marks RE, Turbott SH, et al. 1991b. Methylphenidate and thioridazine in the treatment of intellectually subaverage children: effects on cognitive-motor performance. J Am Acad Child Adolesc Psychiatry 30:816-24.
5. Betancur C, Corbex M, Spielewoy C, et al. 2002. Serotonin transporter gene polymorphisms and hyperserotonemia in autistic disorder. Mol Psychiatry 7:67-71.
6. Birmaher B, Quintana H, Greenhill L. 1988. Methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry 27:248-51.
7. Birmaher B, Ryan N, Williamson DE, et al. 1996. Childhood and adolescent depression: a review of the past ten years, part II. J Am Acad Child Adolesc Psychiatry 35:1575-83.
8. Biswasl PN, Wilton LV, Pearcel GL, et al. 2001. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 15:265-71.
9. Campbell M, Fish B, Shapiro T, et al. 1971. Imipramine in preschool autistic and schizophrenic children. J Autism Childhood Schizophr 1:267-82.
10. Campbell M, Anderson LT, Small AM, et al. 1993. Naltrexone in autistic children: behavior symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 32:1283-91.
11. Campbell M, Schopler E, Cueva JE, et al. 1996. Treatment of autistic disorder. J Am Acad Child Adolesc Psychiatry 35:134-43.
12. Campbell M, Rapoport JL, Simpson GM. 1999. Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:537-45.
13. Carey T, Ratliff-Schaub K, Funk J, et al. 2002. Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism. Journal of Autism and Developmental Disorders 32:161-67.
14. Chez MG, Buchanan CP, Bagan BT, et al. 2000. Secretin and autism: a two-part clinical investigation. J Autism Dev Disord 30:87-94.
15. Chugani DC, Muzik O, Rothermel R, et al. 1997. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol 42:666-69.
16. Coniglio SJ, Lewis JD, Lang C, et al. 2001. A randomized, double-blind, placebocontrolled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr 138:649-55.
17. Connor DF. 1994. Beta blockers for aggression: A review of the pediatric experience. J Child Adolesc Psychopharmacol 3:99-114.
18. Connor DF, Ozbayrak KR, Benjamin S, et al. 1997. A pilot study of nadolol for overt aggression in developmentally delayed individuals. J Am Acad Child Adolesc Psychiatry 36:826-34.
19. Cook EH, Jr., Leventhal BL. 1996. The serotonin system in autism. Curr Opin Pediatr 8(4):348-54.
20. Cook EH Jr, Rowlett R, Jaselskis C, et al. 1992. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 31:739-45.
21. Coplan J, Souders MC, Mulberg AE, et al. 2003. Children with autistic spectrum disorders. II: parents are unable to distinguish secretin from placebo under double-blind conditions. Arch Dis Child 88:737-39.
22. Corbett B, Khan K, Czapansky-Beilman D, et al. 2001. A double-blind, placebocontrolled crossover study investigating the effect of porcine secretin in children with autism. Clin Pediatr 40:327-31.
23. Dunn-Geier J, Ho HH, Auersperg E, et al. 2000. Effect of secretin on children with autism: a randomized controlled trial. Dev Med Child Neurol 42:796-802.
24. Fankhauser MP, Karumanchi VC, German ML, et al. 1992. A double-blind, placebocontrolled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 53(3):77-82.
25. Feeney DJ, Klykylo W. 1996. Risperidone and tardive dyskinesia. J Am Acad Child Adolesc Psychiatry 35:1421-22.
26. Feldman HM, Kolmen BK, Gonzaga AM, et al. 1999. Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiatry 38:584-93.
27. Findling RL, Maxwell K, Wiznitzer M, et al. 1997. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 33(1):155-59.
28. Fukuda T, Sugie H, Ito M, et al. 2001. [Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder]. No to Hattatsu [Brain and Development] 33:314-18. (In Japanese.)
29. Gordon CT, State RC, Nelson JE, et al. 1993. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psych 50:441-47.
30. Hagg S, Soderberg S, Ahren B, et al. 2001. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 62:843-48.
31. Henderson DC. 2002. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 16:77-89.
32. Hollander E. 1998. Treatment of obsessive-compulsive spectrum disorders with SSRIs. Br J Psychiatry 35(Suppl):7-12.
33. Horrigan JP, Barnhill LJ. 1997. Risperidone and explosive aggressive autism. J Autism Dev Disord 27:313-23.
34. Horvath K, Stefanatos G, Sokolski KN, et al. 1998. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minority Physicians 9:9-15.
35. Jaselskis CA, Cook EH, Fletcher KE, et al. 1992. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322-27.
36. Kemper TL, Bauman M. 1998. Neuropathology of infantile autism. J Neuropathol Exp Neurol 57:645-52.
37. Kern JK, Miller VS, Evans PA, et al. 2002. Efficacy of porcine secretin in children with autism and pervasive developmental disorder. J Autism Dev Disord 32:153-59.
38. Kolmen BK, Feldman HM, Handen BL, et al. 1995. Naltrexone in young autistic children. J Am Acad Child Adolesc Psychiatry 34:223-31.
39. Kolmen BK, Feldman HM, Handen BL, et al. 1997. Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry 36:1570-78.
40. Kumar S, Malone DM. 2000. Risperidone implicated in the onset of tardive dyskinesia in a young woman. Postgrad Med J 76:316-17.
41. Leboyer M, Bouvard MP, Launay J, et al. 1992. Brief report: a double-blind study of naltrexone in infantile autism. J Autism Dev Disord 22:309-19.
42. Leboyer M, Philippe A, Bouvard MP, et al. 1999. Whole blood serotonin and plasma betaendorphin in autistic probands and their first-degree relatives. Biol Psychiatry 45:158-63.
43. Levy SE, Souders MC, Wray J, et al. 2003. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin. Arch Dis Child 88:731-36.
44. Malone RP, Cater J, Sheikh RM, et al. 2001. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 40:887-94.
45. Malone RP, Maislin G, Choudhury MS, et al. 2002. Risperidone treatment in children and adolescents with autism: short-and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41:140-47.
46. McDougle CJ, Naylor ST, Cohen DJ, et al. 1996. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-8.
47. McDougle CJ, Holmes JP, Bronson MR, et al. 1997. Rispiradone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 36:685-93.
48. McDougle CJ, Holmes JP, Carlson DC, et al. 1998. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55:633-41.
49. Molloy CA, Manning-Courtney P, Swayne S, et al. 2002. Lack of benefit of intravenous synthetic human secretin in the treatment of autism. J Autism Dev Disord 32:545-51.
50. Newcomer JW, Haupt DW, Fucetola R, et al. 2002. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337-45.
51. Nicolson R, Awad G, Sloman L, et al. 1998. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 37:372-76.
52. Owley T, McMahon W, Cook EH, et al. 2001. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. J Am Acad Child Adolesc Psychiatry 40:1293-99.
53. Panksepp J, Lensing P. 1991. Brief report: a synopsis of an open trial of naltrexone treatment of autism with four children. J Autism Dev Disord 21:243-49.
54. Potenza MN, Holmes JP, Kanes SJ, et al. 1999. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19:37-44.
55. Quintana H, Birmaher B, Stedge D, et al. 1995. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 25:283-94.
56. Roberts W, Weaver L, Brian J, et al. 2001. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics 107:107-11.
57. Ryan ND. 1992. The pharmacologic treatment of child and adolescent depression. Psychiatric Clin N Am 15:29-40.
58. Sanchez L, Campbell M, Small AM, et al. 1996. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 35:537-44.
59. Sandler AD, Sutton KA, DeWeese J, et al. 1999. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med 341:1801-6.
60. Sernyak MJ, Leslie DL, Alarcon RD, et al. 2002. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561-66.
61. Singh VK, Singh EA, Warren RP, et al. 1997. Hyperserotoninemia and serotonin receptor antibodies in children with autism but not mental retardation. Biol Psychiatry 41:753-55.
62. Steingard RJ, Zimnitzky B, DeMAso DR, et al. 1997. Sertraline treatment of transitionassociated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 7:9-15.
63. Unis AS, Munson JA, Rogers SJ, et al. 2002. A randomized, double-blind, placebocontrolled trial of porcine versus synthetic secretin for reducing symptoms of autism. J Am Acad Child Adolesc Psychiatry 41:1315-21.
64. Willemsen-Swinkels SHN, Buitelaar JK, Weijen FG, et al. 1995a. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Arch Gen Psychiatry 52:766-73.
65. Willemsen-Swinkels SHN, Buitelaar JK, Nijhof GF, et al. 1995b. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 58:203-15.
66. Willemsen-Swinkels SHN, Buitelaar JK, van Engeland H, et al. 1996. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebocontrolled crossover study. Biol Psychiatry 39:1023-31.